Adagene Inc. (ADAG)
NASDAQ: ADAG · IEX Real-Time Price · USD
2.510
-0.060 (-2.33%)
At close: Jul 19, 2024, 4:00 PM
2.640
+0.130 (5.18%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Adagene Revenue
In the year 2023, Adagene had annual revenue of $18.11M with 94.90% growth.
Revenue (ttm)
$18.11M
Revenue Growth
+94.90%
P/S Ratio
6.11
Revenue / Employee
$104,089
Employees
174
Market Cap
110.74M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 140.46M |
| Journey Medical | 80.00M |
| TELA Bio | 63.15M |
| Augmedix | 48.70M |
| Elutia | 28.99M |
| Armata Pharmaceuticals | 4.70M |
| I-Mab | 3.90M |
| aTyr Pharma | 588.00K |
ADAG News
- 10 days ago - Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - GlobeNewsWire
- 2 months ago - Adagene to Present at Investor Conferences in June - GlobeNewsWire
- 4 months ago - Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewsWire
- 5 months ago - Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire
- 5 months ago - Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl - GlobeNewsWire
- 6 months ago - Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 7 months ago - Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium - GlobeNewsWire